168 related articles for article (PubMed ID: 20228585)
1. Re-evaluation of the serum alanine aminotransferase upper normal limit in chronic hepatitis C patients.
Yagura M; Tanaka A; Kamitsukasa H; Otsuka H; Kanno S; Aoyama T
Intern Med; 2010; 49(6):525-8. PubMed ID: 20228585
[TBL] [Abstract][Full Text] [Related]
2. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
[TBL] [Abstract][Full Text] [Related]
3. Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, an endemic area for hepatitis B.
Hung KY; Lee KC; Yen CJ; Wu KD; Tsai TJ; Chen WY
Nephrol Dial Transplant; 1997 Jan; 12(1):180-3. PubMed ID: 9157333
[TBL] [Abstract][Full Text] [Related]
4. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
[TBL] [Abstract][Full Text] [Related]
6. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
[TBL] [Abstract][Full Text] [Related]
7. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.
Gordon SC; Fang JW; Silverman AL; McHutchison JG; Albrecht JK
Hepatology; 2000 Aug; 32(2):400-4. PubMed ID: 10915749
[TBL] [Abstract][Full Text] [Related]
8. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
He LT; Ye XG; Zhou XY
World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
[TBL] [Abstract][Full Text] [Related]
9. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
[TBL] [Abstract][Full Text] [Related]
10. PEG-IFNalpha/RBV combination therapy for chronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate.
Yada N; Kudo M; Chung H; Hayaishi S; Takita M; Ueda T; Tatsumi C; Hatanaka K; Kitai S; Ishikawa E; Inoue T; Hagiwara S; Ueshima K
Intervirology; 2010; 53(1):60-5. PubMed ID: 20068343
[TBL] [Abstract][Full Text] [Related]
11. After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal.
El Kassas M; Alboraie M; Mostafa A; Ezzat R; El Tahan A; Afify S; Sweedy A; Kabbash I; Esmat G
J Clin Lab Anal; 2018 Mar; 32(3):. PubMed ID: 28752960
[TBL] [Abstract][Full Text] [Related]
12. Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea.
Sohn W; Jun DW; Kwak MJ; Park Q; Lee KN; Lee HL; Lee OY; Yoon BC; Choi HS
J Gastroenterol Hepatol; 2013 Mar; 28(3):522-9. PubMed ID: 22497339
[TBL] [Abstract][Full Text] [Related]
13. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
14. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis.
Fabrizi F; Lunghi G; Finazzi S; Colucci P; Pagano A; Ponticelli C; Locatelli F
Am J Kidney Dis; 2001 Nov; 38(5):1009-15. PubMed ID: 11684554
[TBL] [Abstract][Full Text] [Related]
15. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
Basso M; Giannini EG; Torre F; Blanchi S; Savarino V; Picciotto A
Hepatology; 2009 May; 49(5):1442-8. PubMed ID: 19350657
[TBL] [Abstract][Full Text] [Related]
16. Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy.
Murdaca G; Contini P; Cagnati P; Marenco S; Pieri G; Lantieri F; Picciotto A; Puppo F
Clin Exp Med; 2017 Feb; 17(1):93-100. PubMed ID: 26567007
[TBL] [Abstract][Full Text] [Related]
17. The effect of increased oxidative stress and ferritin in reducing the effectiveness of therapy in chronic hepatitis C patients.
Chiou YL; Chen YH; Ke T; Ko WS
Clin Biochem; 2012 Nov; 45(16-17):1389-93. PubMed ID: 22760008
[TBL] [Abstract][Full Text] [Related]
18. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
19. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
20. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
